- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
PDK1 AntibodyRabbit Monoclonal Antibody
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AJ1597b | 100ul 400 ul | 2-3 days | $ 315.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
PDK1 Antibody - Product info | |
| Application | WB, IHC
|
| Primary Accession | O15530 |
| Reactivity | Human, Mouse |
| Clone Names | EP569Y |
| Calculated MW | 63152 Da |
| Gene ID 5170 | |
| Other Names Cd79b, Igb, B-cell antigen receptor complex-associated protein beta chain, Ig-beta;B-cell-specific glycoprotein B29;Immunoglobulin-associated B29 protein | |
| Target/Specificity A synthetic phospho-peptide corresponding to residues surrounding Tyr373 and Tyr376 of human PDK1 was used as immunogen. This antibody will detect both phosphorylated and non-phosphorylated targets. | |
| Dilution WB~~1:1000 IHC~~1:100~250 | |
| Format 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions PDK1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. | |
PDK1 Antibody - Protein Information | |
| Name PDPK1 | |
| Synonyms PDK1 | |
| Function Serine/threonine kinase which acts as a master kinase, phosphorylating and activating a subgroup of the AGC family of protein kinases. Its targets include: protein kinase B (PKB/AKT1, PKB/AKT2, PKB/AKT3), p70 ribosomal protein S6 kinase (RPS6KB1), p90 ribosomal protein S6 kinase (RPS6KA1, RPS6KA2 and RPS6KA3), cyclic AMP-dependent protein kinase (PRKACA), protein kinase C (PRKCD and PRKCZ), serum and glucocorticoid-inducible kinase (SGK1, SGK2 and SGK3), p21-activated kinase-1 (PAK1), protein kinase PKN (PKN1 and PKN2). Plays a central role in the transduction of signals from insulin by providing the activating phosphorylation to PKB/AKT1, thus propagating the signal to downstream targets controlling cell proliferation and survival, as well as glucose and amino acid uptake and storage. Negatively regulates the TGF-beta-induced signaling by: modulating the association of SMAD3 and SMAD7 with TGF-beta receptor, phosphorylating SMAD2, SMAD3, SMAD4 and SMAD7, preventing the nuclear translocation of SMAD3 and SMAD4 and the translocation of SMAD7 from the nucleus to the cytoplasm in response to TGF-beta Activates PPARG transcriptional activity and promotes adipocyte differentiation. Activates the NF-kappa-B pathway via phosphorylation of IKKB. The tyrosine phosphorylated form is crucial for the regulation of focal adhesions by angiotensin II Controls proliferation, survival, and growth of developing pancreatic cells. Participates in the regulation of Ca(2+) entry and Ca(2+)-activated K(+) channels of mast cells. Essential for the motility of vascular endothelial cells (ECs) and is involved in the regulation of their chemotaxis. Plays a critical role in cardiac homeostasis by serving as a dual effector for cell survival and beta-adrenergic response. Plays an important role during thymocyte development by regulating the expression of key nutrient receptors on the surface of pre-T cells and mediating Notch-induced cell growth and proliferative responses. Provides negative feedback inhibition to toll-like receptor-mediated NF- kappa-B activation in macrophages. Isoform 3 is catalytically inactive | |
| Cellular Location Cytoplasm. Nucleus. Cell membrane; Peripheral membrane protein. Cell junction, focal adhesion Note=Tyrosine phosphorylation seems to occur only at the cell membrane. Translocates to the cell membrane following insulin stimulation by a mechanism that involves binding to GRB14 and INSR. SRC and HSP90 promote its localization to the cell membrane Its nuclear localization is dependent on its association with PTPN6 and its phosphorylation at Ser-396. Restricted to the nucleus in neuronal cells while in non-neuronal cells it is found in the cytoplasm. The Ser-241 phosphorylated form is distributed along the perinuclear region in neuronal cells while in non- neuronal cells it is found in both the nucleus and the cytoplasm IGF1 transiently increases phosphorylation at Ser-241 of neuronal PDPK1, resulting in its translocation to other cellular compartments. The tyrosine-phosphorylated form colocalizes with PTK2B in focal adhesions after angiotensin II stimulation | |
| Tissue Location Appears to be expressed ubiquitously. The Tyr- 9 phosphorylated form is markedly increased in diseased tissue compared with normal tissue from lung, liver, colon and breast | |
PDK1 Antibody - Related products
AP3213a: Phospho-PDK1-S241 Antibody
AP3405a: Phospho-PDPK1-S393 Antibody
AP3458a: Phospho-PDPK1-S396 Antibody
AP3466a: Phospho-PDPK1-S241 Antibody
AP3467a: Phospho-PDPK1-S410 Antibody
AP3476a: Phospho-PDPK1-Y9 Antibody
AP7042a: PDK1 (PDPK1) Antibody (N-term H67)
AP7042b: PDK1 (PDPK1) Antibody (C-term)
AP7042c: PDPK1 Antibody (S396)
AP7042d: PDK1 (PDPK1) Antibody (N-term P71)
AP7042e: PDK1 (PDPK1) Antibody (S241)
AP7042f: PDK1 (PDPK1) Antibody (S410)
AP7042g: PDK1 (PDPK1) Antibody (Y9)
AP7042h: PDPK1 Antibody (S393)
RI13899: PDPK1 predesign siRNA
LY11499a: PDPK1 Over-expression Lysate
BP3405a: Phospho-PDPK1-S393 Antibody Blocking Peptide
BP3458a: Phospho-PDPK1-S396 Antibody Blocking Peptide
BP3466a: Phospho-PDPK1-S241 Antibody Blocking Peptide
BP3467a: Phospho-PDPK1-S410 Antibody Blocking Peptide
BP3476a: Phospho-PDPK1-Y9 Antibody Blocking Peptide
BP7042a: PDPK1 Antibody (N-term) Blocking Peptide
BP7042b: PDPK1 Antibody (C-term) Blocking Peptide
BP7042c: PDPK1 Antibody (S396) Blocking Peptide
BP7042d: PDPK1 Antibody (N-term P71) Blocking Peptide
BP7042e: PDPK1 Antibody (S241) Blocking Peptide
BP7042f: PDPK1 Antibody (S410) Blocking Peptide
BP7042g: PDPK1 Antibody (Y9) Blocking Peptide
PDK1 Antibody - Application data
-
A. Western blot analysis on 293 cell lysate using anti- PDK1 RabMAb (Cat. #AJ1597b), 1:1000 dilution.
-
B. Immunohistochemical analysis of human prostate carcinoma using anti-PDK1 RabMAb (Cat. #AJ1597b).
PDK1 Antibody - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
3-Phosphoinositide-dependent protein kinase-1 (PDK1) is a serine/threonine protein kinase known to phosphorylate and activate PKB/AKT (Thr308 and Ser473), p70 S6 kinase, RSK, PKA, PKC and SGK. Upon stimulation of receptor tyrosine kinases, PI3K becomes activated and generates the phospholipid second messengers, PtdIns(3,4,5)P 3 and PtdIns(3,4)P 2, which in turn mediate the phosphorylation and activation of PDK1 targets through diverse mechanisms (1-2). It has also been shown that stimulation of cells with pervanadate and IGF-1 results in a significant increase in PDK1 activity and translocation to the plasma membrane along with an increase in tyrosine phosphorylation (3). Only phosphorylation on the activation loop at Ser241 is necessary for PDK1s activity and a single nucleotide mutation abolishes its activity (4).
REFERENCES
1. Alessi et al. Curr. Biol. 7:776-789, 1997
2. Stokoe et al. Science 277:567-570, 1997
3. Jongsun P, et al. J. Biol. Chem. 276(40):37459-71, 2001
4. Casamayor A, Biochem. J. 342, 287-292, 1999.